ACR Convergence 2024 marks UCB's first presentation of data in psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) since the recent approvals of BIMZELX ® (bimekizumab-bkzx) in these indications in the U.S. New two-year data demonstrated sustained improvements in clinical and patient-reported outcomes in PsA, nr-axSpA, and AS patients treated with BIMZELX UCB will present 19 BIMZELX abstracts, including two oral presentations, across PsA, nr-axSpA, and AS, as well as plaque psoriasis (PSO) ATLANTA , Nov.
14, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the presentation of new two-year data confirming a sustained clinical response for the IL-17A and IL-17F inhibitor BIMZELX ® (bimekizumab-bkzx), in adults with active psoriatic arthritis (PsA) and those with active non-radiographic axial spondyloarthritis with objective signs of inflammation (nr-axSpA) and active ankylosing spondylitis (AS). These results are the latest from the Phase 3 studies BE OPTIMAL (PsA), BE COMPLETE (PsA), and their open-label extension BE VITAL, as well as BE MOBILE 1 (nr-axSpA), BE MOBILE 2 (AS), and their open-label extension BE MOVING. 1,2,3 Additionally, new one-year data demonstrated significant reduction in inflammation and structural lesions in nr-axSpA and AS, as assessed by magnetic resonance imaging (MRI), while two-year data confirmed minimal spinal radiographic progression in nr-axSpA and AS.
4,5 .
